Rapport Therapeutics (NASDAQ:RAPP) Shares Sold by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. decreased its stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) by 5.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,636,931 shares of the company's stock after selling 90,180 shares during the period. T. Rowe Price Investment Management Inc. owned 4.47% of Rapport Therapeutics worth $29,040,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new position in shares of Rapport Therapeutics in the fourth quarter worth about $34,000. New York State Common Retirement Fund bought a new stake in Rapport Therapeutics in the fourth quarter valued at $62,000. JPMorgan Chase & Co. bought a new position in shares of Rapport Therapeutics in the 3rd quarter worth $83,000. Wells Fargo & Company MN boosted its position in shares of Rapport Therapeutics by 38.9% during the fourth quarter. Wells Fargo & Company MN now owns 4,824 shares of the company's stock valued at $86,000 after buying an additional 1,352 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Rapport Therapeutics during the fourth quarter worth $138,000.

Insider Activity at Rapport Therapeutics

In other Rapport Therapeutics news, Director Wendy B. Young purchased 6,000 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were bought at an average cost of $10.21 per share, for a total transaction of $61,260.00. Following the completion of the purchase, the director now directly owns 6,000 shares of the company's stock, valued at approximately $61,260. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Troy A. Ignelzi acquired 9,900 shares of the stock in a transaction dated Wednesday, March 12th. The shares were bought at an average cost of $10.10 per share, with a total value of $99,990.00. Following the completion of the transaction, the chief financial officer now owns 9,900 shares of the company's stock, valued at approximately $99,990. This represents a ∞ increase in their position. The disclosure for this purchase can be found here.

Rapport Therapeutics Stock Up 4.1 %

Shares of NASDAQ RAPP traded up $0.47 during mid-day trading on Friday, reaching $11.94. 14,912 shares of the company were exchanged, compared to its average volume of 176,463. Rapport Therapeutics has a 1 year low of $6.43 and a 1 year high of $29.74. The stock has a market cap of $435.75 million and a price-to-earnings ratio of -0.86. The firm has a 50-day moving average of $9.90 and a 200 day moving average of $16.18.

Analyst Upgrades and Downgrades

RAPP has been the topic of a number of recent analyst reports. Citizens Jmp started coverage on shares of Rapport Therapeutics in a report on Tuesday, April 8th. They issued a "mkt outperform" rating on the stock. JMP Securities assumed coverage on Rapport Therapeutics in a research note on Tuesday, April 8th. They issued a "market outperform" rating and a $28.00 target price for the company. Four investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $32.67.

Rapport Therapeutics Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.